The announcement of a Phase 2 trial for KDS2010, a potential Alzheimer's treatment, is a positive development for Scilex Holding Company. The inclusion of a U.S. patient cohort in 2025 suggests a commitment to expanding the trial, which could lead to significant advancements and potential market opportunities. This news is likely to positively impact the stock price in the short term as it indicates progress in their drug development pipeline.